(−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity
Journal of Medicinal Chemistry2001Vol. 44(16), pp. 2675–2678
Citations Over TimeTop 10% of 2001 papers
Braj B. Lohray, Vidya Bhushan Lohray, Ashok C. Bajji, Shivaramayya Kalchar, Rajamohan R. Poondra, Srinivas Padakanti, Ranjan Chakrabarti, Reeba K. Vikramadithyan, Parimal Misra, Suresh Juluri, Narsimha Mamidi, Ramanujam Rajagopalan
Abstract
(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPAR alpha and PPAR gamma. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosiglitazone. Compound 6 has also shown good oral bioavailability and impressive pharmacokinetic characteristics. Our study indicates that 6 has great potential as a drug for diabetes and dyslipidemia.
Related Papers
- → FDA Lifts Restrictions on Rosiglitazone(2014)2 cited
- → Rosiglitazone and Cardiovascular Risk – A Review(2012)
- Rosiglitazone compound formula eliminates the side effects of rosiglitazone(2014)
- The progress of clinical study on rosiglitazone(2003)
- → Re-evaluation of the cardiovascular safety of rosiglitazone(2014)